UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000008348
Receipt number R000009820
Scientific Title Clinical effectiveness of daikenchuto (TJ-100) on gastrointestinal symptom after colectomy in colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.
Date of disclosure of the study information 2012/07/04
Last modified on 2020/07/10 09:36:59

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Clinical effectiveness of daikenchuto (TJ-100) on gastrointestinal symptom after colectomy in colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.

Acronym

Clinical effectiveness of daikenchuto (TJ-100) on abdominal pain and distention after cancer resection in the colorectal cancer patients.

Scientific Title

Clinical effectiveness of daikenchuto (TJ-100) on gastrointestinal symptom after colectomy in colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.

Scientific Title:Acronym

Clinical effectiveness of daikenchuto (TJ-100) on abdominal pain and distention after cancer resection in the colorectal cancer patients.

Region

Japan


Condition

Condition

Colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder.

Classification by specialty

Gastrointestinal surgery

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The purpose in this study is to examine a clinical effectiveness of daikenchuto on the gastrointstinal dysfunction-related symptom, such as abdominal pain and distention, and QOL after colectomy in the colorectal cancer patients with abdominal pain and distention due to a bowel movement disorder (prolonged POI high risk patients).

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

1) Gastrointestinal symptom. (abdominal pain /distention/ the sensation of incomplete bowel evacuation)2) number of postoperative day to comfirm first evacuation, number of postoperative time to comfirm first flatus, number of bowel movements per day.

Key secondary outcomes

1) Pass Variance 2) QOL assessment using the GSRS questionnaire.3) number of white blood-cell and Neutrophilic, and CRP levels. 4) Abdominal radiography.5) Ileus and POI onset or not (a definition of ileus: The thing which the neighboring organizations adhere to intestinal tracts or an intestinal tract, and has higher than two items among intestinal tract stricture or an ileus state and abdomen symptoms. (abdominal pain,distention, nausea, vomiting) that it is, and may be related to a symptom of ileus).6) A dose / a rate of laxative


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation


Institution consideration


Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Oral administration of test drug (daikenchuto) 5.0 g per dose as a general rule (15 g/day, t.i.d., before meals) from patiant consent day to preoperative day and postoperative day 2 to postoperative day 28.

Interventions/Control_2

Standard of care.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

In order to participate in this study, a patient must meet all of the following criteria.1) Patient who was judged that an colectomy was possible for treatment of the colon or rectal cancer.Preoperative staging of disease:I, II, IIIa, IIIbTNM category distribution: T=1-3, N=0-2, M=02) Patients with PS (ECOG Performance Status Scale):0, 13) Patients who are diagnosed as pre-operative constipation CTCAE ver.4 grade is at least 1 and abdominal pain and/or distention GSRS score at least 3.4) Age: 20 years or older5) Gender: no specification6) Inpatient/Outpatient: Inpatient7) Patients who can provide written informed consent

Key exclusion criteria

In order to participate in this study, a patient must not meet any of the following criteria.1) Patients with history or at present of chemotherapy and/or radiotherapy for primary disease.2) Patients with lower colectory.3) Patients with concomitant inflammatory bowel disease such as ulcerative colitis and crohn disease.4) Patients with cancerous peritonitis.5) Patients with organic leasion of hepato-biliary-pancreatic (gallstone, hepatitis, pancreatitis)6) Patients with total construction of artificial anus.7) Patients with gastrointestinal hemorrhage, perforation and history of mechanical ileus.8) Patients with serious complications (interstitial pneumonia, diabetes mellitus, heart failure, renal failure, hepatic insufficiency)9) Patients who are administered antiparkinson drug.10) Patients who are pregnant, possibly pregnant, nursing or considering pregnancy.11) Others, patients who are unfit for the study as determined by the attending physician.

Target sample size

60


Research contact person

Name of lead principal investigator

1st name Hiroki
Middle name
Last name Akamatsu

Organization

Osaka Police Hospital

Division name

Surgery

Zip code

543-0035

Address

10-31 Kitayama-cho Tennouji-ku Osaka 543-0035,Japan

TEL

06-6771-6051

Email

wakasugi@oph.gr.jp


Public contact

Name of contact person

1st name Masaki
Middle name
Last name Wakasugi

Organization

Osaka Police Hospital

Division name

Surgery

Zip code

543-0035

Address

0-31 Kitayama-cho Tennouji-ku Osaka 543-0035,Japan

TEL

06-6771-6051

Homepage URL


Email

wakasugi@oph.gr.jp


Sponsor or person

Institute

Osaka Police Hospital

Institute

Department

Personal name



Funding Source

Organization

Tsumura company

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Osaka Police Hospital

Address

10-31 Kitayama-cho Tennouji-ku Osaka 543-0035,Japan

Tel

06-6771-6051

Email

wakasugimasaki@gmail.com


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

大阪警察病院(大阪)/Osaka Police Hospital(Osaka)


Other administrative information

Date of disclosure of the study information

2012 Year 07 Month 04 Day


Related information

URL releasing protocol

pubmed.ncbi.nlm.nih.gov/32588153/

Publication of results

Published


Result

URL related to results and publications

pubmed.ncbi.nlm.nih.gov/32588153/

Number of participants that the trial has enrolled

32

Results

The numbers of bowel movements per day on postoperative days (PODs) 1, 2, and 6 were significantly lower in the DKT group. The presence of the sensation of incomplete bowel evacuation on PODs 3 and 28 was significantly lower in the DKT group. There were no adverse events due to or suspected to be related to DKT.

Results date posted

2020 Year 07 Month 10 Day

Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics

Patients undergoing colorectal surgery at the Osaka Police Hospital

Participant flow

The patients were randomly assigned to either the DKT group or the control group.

Adverse events

None

Outcome measures

Primary endpoints were i) gastrointestinal symptoms (abdominal pain/distention) measured by the Visual Analogue Scale (VAS); ii) the sensation of incomplete bowel evacuation (yes/no); and iii) POD to confirm first evacuation, postoperative time to confirm first flatus, and the number of bowel movements per day. Secondary endpoints included quality of life (QOL) (acid reflux, abdominal pain, indigestion, diarrhea, and constipation) assessment using the GSRS questionnaire. Participants completed the questionnaire on the day of informed consent before the operation (about 2 weeks before surgery) and on PODs 3, 7, 14, 21, and 28.

Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2011 Year 03 Month 04 Day

Date of IRB

2012 Year 06 Month 01 Day

Anticipated trial start date

2012 Year 07 Month 01 Day

Last follow-up date

2016 Year 03 Month 14 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2012 Year 07 Month 04 Day

Last modified on

2020 Year 07 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000009820


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name